SLC5A2 and diabetes mellitus: The EMPEROR-Preserved trial demonstrated a significant 29% reduction in HF-related hospitalizations with empagliflozin, highlighting the efficacy of SGLT2 inhibitors in improving clinical outcomes in HFpEF patients, regardless of diabetes status [5].